HiFD`[email protected] en es it fr

HiFD`[email protected] Brand names, HiFD`[email protected] Analogs

HiFD`[email protected] Brand Names Mixture

  • No information avaliable

HiFD`[email protected] Chemical_Formula


HiFD`[email protected] RX_link


HiFD`[email protected] fda sheet

HiFD`[email protected] FDA

HiFD`[email protected] msds (material safety sheet)

HiFD`[email protected] MSDS

HiFD`[email protected] Synthesis Reference

No information avaliable

HiFD`[email protected] Molecular Weight

149.212 g/mol

HiFD`[email protected] Melting Point

198.5 oC

HiFD`[email protected] H2O Solubility

1.11E+005 mg/L

HiFD`[email protected] State


HiFD`[email protected] LogP


HiFD`[email protected] Dosage Forms

Capsule; Tablet

HiFD`[email protected] Indication

For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis

HiFD`[email protected] Pharmacology

Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy. Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis. It works by reducing numbers of T-lymphocytes, inhibiting macrophage function, decreasing IL-1, decreasing rheumatoid factor, and preventing collagen from cross-linking. Its use in Wilson's disease, a rare genetic disorder of copper metabolism, relies on its binding to accumulated copper and elimination through urine.

HiFD`[email protected] Absorption

rapidly but incompletely

HiFD`[email protected] side effects and Toxicity

No information avaliable

HiFD`[email protected] Patient Information

No information avaliable

HiFD`[email protected] Organisms Affected

Humans and other mammals